Paclitaxel given during surgery for stomach cancer spread to the belly
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older.
- You can take care of yourself and do daily activities fairly well (ECOG 0–2).
- Your stomach or gastroesophageal junction cancer is confirmed as adenocarcinoma by tissue or fluid testing.
- Your blood counts and kidney function are good enough for chemotherapy (specific lab thresholds must be met).
- Your cancer must be limited to the belly lining: either positive peritoneal cytology or cancer seen during diagnostic laparoscopy/laparotomy.
- You finished the planned preoperative chemotherapy; certain targeted treatments or immunotherapy may still be allowed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
This trial tests if surgery to remove visible cancer in the belly combined with heated chemotherapy placed directly into the abdomen can help people with stomach cancer that has spread to the lining of the belly. It is for patients who are well enough to undergo major surgery and meet specific health requirements.
This trial tests a chemotherapy drug (paclitaxel) given directly into the belly for people whose appendix cancer has spread inside the belly and cannot be surgically removed. The goal is to see if this approach is safe and helps shrink tumors.
This trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard intravenous chemotherapy improves outcomes for people with stomach or esophageal cancer that has spread to the lining of the abdomen (peritoneal metastasis).
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.